Pantop%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome. * Reduction of risk of NSAID-associated gastric ulcers in patients with a history of such ulcers who are taking NSAIDs. ## Adult Dosing * **Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. * **Maintenance of Healing:** 40 mg orally once daily. Doses of 20 mg orally once daily may be sufficient for some patients. * **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be increased as needed. Maximum recommended dose is 240 mg daily. * **NSAID-Associated Gastric Ulcer Prophylaxis:** 40 mg orally once daily. ## Pediatric Dosing * **GERD (Erosive Esophagitis):** * **1 to 5 years:** 20 mg orally once daily for up to 8 weeks. * **5 to 12 years:** 40 mg orally once daily for up to 8 weeks. * **12 to 17 years:** 40 mg orally once daily for up to 8 weeks. * **Note:** Intravenous dosing in pediatric patients is not well-established and should be guided by specialist recommendations and local protocols. ## Dose Adjustments No specific dose adjustments are typically required for hepatic or renal impairment. ## Contraindications * Known hypersensitivity to pantoprazole, any component of the formulation, or any other substituted benzimidazole. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, flatulence. * **Serious:** * Increased risk of *Clostridium difficile*-associated diarrhea. * Bone fracture (hip, wrist, spine) with long-term use. * Hypomagnesemia (can be asymptomatic or present with fatigue, muscle spasms, tetany, seizures, arrhythmias). * Vitamin B12 deficiency with prolonged use. * Possible increased risk of certain infections (e.g., pneumonia). * Cutaneous and systemic lupus erythematosus. ## Key Drug Interactions * **Warfarin:** Increased INR and bleeding risk. Monitor INR closely. * **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Consider dose reduction of methotrexate or temporary discontinuation of pantoprazole. * **Certain HIV Medications (e.g., rilpivirine, atazanavir):** Pantoprazole can decrease their absorption due to increased gastric pH. Avoid concomitant use. * **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May affect metabolism of drugs like clopidogrel, diazepam, and phenytoin. ## Monitoring * Monitor for signs and symptoms of *Clostridium difficile*-associated diarrhea. * Assess for magnesium levels, especially in patients on prolonged therapy or concomitant diuretic use. * Consider monitoring vitamin B12 levels in patients on long-term therapy. * Monitor bone mineral density in patients at risk for osteoporosis. ## Clinical Pearls * Administer pantoprazole 30 minutes before a meal for optimal efficacy. * Do not crush or chew delayed-release tablets; swallow whole. * For IV administration, reconstitute and dilute according to manufacturer instructions. * Long-term use of PPIs is associated with potential risks; use the lowest effective dose for the shortest duration necessary. * Consider vitamin B12 supplementation if deficiency is suspected or confirmed. *** **Disclaimer:** This information is intended for educational purposes and does not replace current prescribing information. Always consult the most up-to-date drug monograph and local protocols for complete and accurate guidance.